-

10:48:00 AM

ABBV Stock News

ABBV - Abbvie Inc

02/03/21 7:38 AM

NYSE : ABBV

earnings

AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results

AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the

RHEA-AI

positive

01/26/21 8:45 AM

NYSE : ABBV

CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite

Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of CoolSculpting ® Elite, its next generation fat reduction system with applicators designed to complement the body's natural curves. CoolSculpting ® Elite harnesses proven

RHEA-AI

neutral

01/25/21 11:30 AM

NYSE : ABBV

European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis

AbbVie (NYSE: ABBV), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis (PsA) in adult patients

RHEA-AI

neutral

01/15/21 9:00 AM

NYSE : ABBV

conferences

Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference

Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key

RHEA-AI

positive

01/12/21 4:05 PM

NYSE : ABBV

acquisition

Allergan Aesthetics Enters Into Option to Acquire Cypris Medical

Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be

RHEA-AI

neutral

01/12/21 8:00 AM

NYSE : ABBV

conferencesearnings

AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be

RHEA-AI

neutral

01/12/21 6:45 AM

NYSE : ABBV

Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate

Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate

RHEA-AI

very positive

01/07/21 8:45 AM

NYSE : ABBV

clinical trial

Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease

AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of risankizumab (600 mg and 1200 mg) met both primary endpoints of clinical remission and endoscopic response at week

RHEA-AI

neutral

01/06/21 8:00 AM

NYSE : ABBV

conferences

AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Members of AbbVie's executive leadership team will present virtually at 3:30 p.m. Central time, including Richard A. Gonzalez,

RHEA-AI

neutral

01/05/21 8:48 AM

NYSE : ABBV

clinical trial

Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients

AbbVie (NYSE: ABBV) today announced positive top-line results from two Phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and KEEPsAKE-2, showing that significantly more patients treated with risankizumab (150 mg) achieved the

RHEA-AI

neutral

Prev 4 5 6 7 8 9 10 11 12 13 Next

ABBV Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.abbvie.com
CeoRichard Gonzalez
Security nameAbbvie Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2020
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1 N Waukegan Rd
StateIllinois
CityNorth Chicago
Zip60064-1802
CountryUS
Phone18479327900

ABBV Description:

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.